Perceptive Advisors LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $6.96 Million - $7.37 Million	-170,317 Reduced 1.55%	10,794,876 $456 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $17.8 Million - $37.2 Million	876,808 Added 8.69%	10,965,193 $465 Million
Q2 2023 Aug 24, 2023	BUY	$23.9 - $35.38 $4.07 Million - $6.03 Million	170,317 Added 1.72%	10,088,385 $321 Million
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $81.4 Million - $121 Million	3,406,341 Added 52.31%	9,918,068 $315 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $36.3 Million - $59 Million	1,425,000 Added 28.01%	6,511,727 $184 Million
Q3 2021 Dec 03, 2021	SELL	$21.26 - $38.85 $1.9 Million - $3.46 Million	-89,140 Reduced 1.72%	5,086,727 $150 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $11.3 Million - $20.7 Million	532,772 Added 11.47%	5,175,867 $153 Million
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $1.23 Million - $1.76 Million	99,033 Added 2.18%	4,643,095 $63.7 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $44.6 Million - $83 Million	4,544,062 New	4,544,062 $75.3 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.